Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Novel anticoagulant serpin described by U.S. academics

Dec. 14, 1998

Avigen presents results of preclinical testing of hemophilia gene therapy and plans clinical trials

Dec. 10, 1998

The Medicines Company begins phase III testing of Hirulog in heart attack patients

Dec. 10, 1998

Prodrug of platelet gpIIb/IIIa receptor antagonist with excellent intranasal antithrombotic efficacy

Dec. 9, 1998

Australian university scientists design new diflunisal esters with improved characteristics

Dec. 8, 1998

Centocor will market Retavase exclusively in the U.S. starting in January

Dec. 4, 1998

Pharming and Gem to codevelop human lactoferrin (GPX-400) to neutralize heparin

Dec. 4, 1998

rNAPc2 enters phase II trials in U.S. and Europe

Dec. 3, 1998

First clinical trial of human gene therapy for hemophilia begins

Dec. 3, 1998

U.S. patent covers transgenically produced rhATIII

Dec. 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...